Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Meet Our
Team

Dr. Joshua Seigel

Advisor

Psychiatrist, Neuroscientist, Clinical Trials Researcher

Dr. Siegel received a BA in Philosophy, Neuroscience and Psychology from Washington University, completed an MD & PhD in systems neuroscience in WUSM’s Physician Scientist Training Program and completed residency in Psychiatry.

Dr. Siegel has 13 years experience in neuroimaging and has published more than 30 peer-reviewed articles in the fields of neuroscience and neuropsychopharmacology including clinical trials with ketamine and psilocybin.

During psychiatry residency, Dr. Siegel initiated Missouri’s first human psychedelics research, using precision functional mapping to study how psilocybin alters brain networks. In addition to conceiving and designing this
research program, he served as a psychedelic ‘facilitator’, completing training with Usona Institute in Madison WI. He was selected to be among 12 US recipients of the NIMH Outstanding Resident Award in 2020.

His research focuses on using human neuroimaging to understand ketamine, psilocybin, and similar molecules that rapidly stimulate plasticity. The central goal is to understand the link between neurotrophic stimulation, brain networks, mood and human behavior. In addition to founding WU’s Program in Psychedelics Research**, he has serves as Deputy Editor at the Journal of Psychedelic Psychiatry, created a graduate course “Mechanisms of Rapid Antidepressants”, founded the WU Rapid Antidepressants Journal Club, and served on the advisory board for psychedelics startups.

**with generous support from the Department of Psychiatry, Usona Institute, the Taylor Family Institute Fund for Innovative Psychiatric Research, the McDonnell Center for Systems Neuroscience, and Ginger Nicol and the Healthy Mind Lab